Massmutual Trust Co. FSB ADV Decreases Stock Position in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL)

Massmutual Trust Co. FSB ADV cut its holdings in Cryo-Cell International, Inc. (NYSEAMERICAN:CCELFree Report) by 2.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 111,035 shares of the company’s stock after selling 3,178 shares during the quarter. Massmutual Trust Co. FSB ADV owned about 1.34% of Cryo-Cell International worth $828,000 at the end of the most recent reporting period.

Separately, Rowlandmiller & PARTNERS.ADV purchased a new position in shares of Cryo-Cell International in the first quarter worth about $108,000. Institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Stock Up 4.3 %

Cryo-Cell International stock traded up $0.35 during midday trading on Thursday, hitting $8.47. 584 shares of the company were exchanged, compared to its average volume of 10,272. The firm has a market cap of $68.61 million, a price-to-earnings ratio of -7.00 and a beta of 0.48. Cryo-Cell International, Inc. has a fifty-two week low of $3.67 and a fifty-two week high of $9.50.

Cryo-Cell International (NYSEAMERICAN:CCELGet Free Report) last issued its quarterly earnings data on Monday, April 15th. The company reported $0.07 EPS for the quarter. Cryo-Cell International had a negative return on equity of 64.31% and a negative net margin of 31.02%. The company had revenue of $7.85 million for the quarter.

About Cryo-Cell International

(Free Report)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.

Further Reading

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with's FREE daily email newsletter.